Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

Morschhauser et al. (Wed,) studied this question.

www.synapsesocial.com/papers/6a01ae96950a93c470d8b35e — DOI: https://doi.org/10.1200/jco.22.00843

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas· 1999 · 3,490 citations
2. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule· 2004 · 567 citations
3. Transformed follicular lymphoma· 2017 · 90 citations
4. Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma· 2005 · 170 citations
5. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.· 2017 · 80 citations